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Edited by Ned ManteiAbstract Histone deacetylase inhibitors (HDIs) are thought to
act primarily at the level of transcription inducing cell cycle
arrest, diﬀerentiation and/or apoptosis in many cancer cell types.
Induction of the potent cdk/cyclin inhibitor p21WAF1 is a key
feature of this HDI mediated transcriptional re-programming
phenomenon. However, in the current study we report that HDIs
are also capable of inducing p21WAF1 through purely post-
transcriptional events, namely increased mRNA stability. These
studies highlight our growing appreciation for the complexities of
HDI mediated eﬀects and challenge our preconceptions regard-
ing the action of these promising anti-neoplastics.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
Keywords: mRNA stability; Histone deacetylase inhibitor;
p21WAF11. Introduction
A number of histone deacetylase inhibitors (HDIs) are being
analyzed at the clinical level [1–4]. However, it is not precisely
understood how HDIs elicit their anti-neoplastic eﬀects. Hy-
potheses have been generated which suggest that HDIs are
transcriptional activators that disrupt the balance between
histone deacetylase (HDAC) and histone acetyl transferase
(HAT) activity resulting in hyperacetylation of nucleosomal
histones and non-histone proteins, such as the transcription
factor p53 [5,6]. The cyclin-dependent kinase inhibitor,
p21WAF1, is the most extensively studied HDI responsive gene
and the only known gene whose activation has been linked to
HDI mediated cell cycle arrest [7]. Gene expression of p21WAF1
is directly upregulated by HDIs in a p53 independent fashion,
but requires one or more Sp1 binding sites in the p21WAF1
proximal promoter for transcriptional activation by these
agents [8,9]. Furthermore, p21WAF1 ﬁts the classical model of
HDI mediated induction, as acetylation of core promoter hi-
stones H3 and H4 correlates with increased gene expression* Corresponding author. Fax: +1-306-655-2635.
E-mail address: kbonham@scf.sk.ca (K. Bonham).
Abbreviations: HDI, histone deacetylase inhibitor; NaB, sodium
butyrate; TSA, trichostatin A; HDAC, histone deacetylase; HAT,
histone acetyl transferase; CHX, cycloheximide; Act. D, actinomycin
D; CAT, chloramphenicol acetyl transferase
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doi:10.1016/j.febslet.2004.06.018[10]. However, recent evidence implies that the phosphatidyl-
inositol 3-kinase and protein kinase C epsilon signaling path-
way is required in addition to increased histone acetylation for
p21WAF1 activation [9,11]. Moreover, HDIs regulate only 2–5%
of cellular genes and have also been reported to repress a
number of genes, including the proto-oncogene c-myc and the
colon oncogene c-Src [12,13]. Therefore, these more recent
observations suggest that histone hyperacetylation may not be
the only fundamental mechanism underlying HDI mediated
changes in gene expression. Here we report that in a human
hepatocellular carcinoma cell line, HepG2, HDIs are incapable
of directly activating the p21WAF1 promoter. Instead, the HDI
mediated induction of p21WAF1 mRNA and protein results
from a dramatic increase in p21WAF1 mRNA stability. These
ﬁndings further challenge the preconception that HDIs solely
regulate changes in gene expression by histone acetylation and
transcriptional activation.2. Materials and methods
2.1. Cell culture and treatments
The cell lines utilized in these experiments were obtained from the
American Type Culture Collection (ATCC). The HT29 colon carci-
noma cells were maintained in Dulbecco’s modiﬁed Eagle’s medium.
HepG2, hepatocellular carcinoma cells were grown in Dulbecco’s
modiﬁed Eagle’s medium and Ham’s F-12 medium. All cells were
supplemented with 10% fetal bovine serum (HyClone Laboratories,
Inc.) and 1% penicillin/streptomycin (Gibco) and grown at 37 C and
5% CO2. For HDI treatments, 5 mM sodium butyrate (NaB, Sigma),
or 1 lM trichostatin A (TSA, Sigma) was added directly to the media
of cells grown to approximately 50% conﬂuency, and harvested at
various time points. Similarly, cells were treated with 50 lM Cyclo-
heximide (CHX, Sigma) in the absence or presence of HDIs. For
mRNA half-life studies, 5 lg/ml Actinomycin D (Act. D, Sigma) was
added directly to the media of cells grown to 50% conﬂuency.2.2. Plasmid constructs
The human wild-type WAF1 promoter–luciferase fusion plasmid,
WWP-Luc, was a kind gift from Dr. B. Vogelstein (Howard Hughes
Medical Institute, Johns Hopkins University). The 2.3 kb WAF1
promoter fragment was isolated by HindIII digestion and subcloned
into the HindIII site of the pBlue vector (Stratagene). The )210WAF1
promoter was constructed by PstI digestion and re-ligation prior to
removal from pBlue with SacI and cloning into SacI digested pCAT3-
Basic (Promega). The )101WAF1 CAT promoter construct was de-
signed by introducing a SacI site through site directed mutagenesis,
using the mutagenic primers sense: 50GGGCGGTCCCGGGCGGAG-
CTCTGGGCCGAGCGAGGGTCCC30 and antisense: 50GGGAC
CCGCGCTCGGCCCAGAGCTCCGCCCGGGACCGCCC30. Theblished by Elsevier B.V. All rights reserved.
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)101WAF1 CAT.
2.3. Growth curve experiments
HepG2 cells were seeded at 1.0 105 cells per 35 mm tissue culture
plate and allowed to grow under normal conditions for a 48 h time
period. At this time the media was changed and the cells treated with
diﬀerent doses of NaB (mM) or TSA (lM). Cells were trypsinized and
counted with a Coulter Counter ZM (Coulter Electronics, Inc.) 24, 48,
72, and 96 h following treatment. The growth curve data presented is
the result of at least two independent experiments.
2.4. RNA extraction and northern blot analysis
Total RNA was isolated from cells by the guanidinium thiocyanate
methodoutlined byChomczynski andSacchi [14] and resuspended in 0.1
mM EDTA containing diethyl pyrocarbonate (DEPC) water. Fifteen
microgram samples of total RNA were separated on a 1% denaturing
formaldehyde-agarose gels, transferred to GeneScreen Plus hybridiza-
tion transfer membranes (Perkin–Elmer Sciences) and UV cross-linked.
cDNA probes as previously described [13] were randomly labeled with
[a-32P]dCTP using Ready-To-Go DNA Labelling Beads (Amersham
Biosciences). Images were acquired by use of a Bio-Rad Molecular Im-
ager FX following exposure to an Imaging Screen K (Kodak) or by
autoradiography at )80 Cwith the aid of an intensiﬁer screen (Kodak).
2.5. Immunoblot analysis
Cells were harvested following HDI treatment at selected time points
in an SDS sample buﬀer containing 10% (w/v) glycerol, 5% b-
mercaptoethanol, 2% (w/v) sodium dodecyl hydrogen sulfate, 65 mM
Tris, and 0.05% (w/v) bromophenol blue to pH 6.8. A Lowry Assay
(Sigma) was used to determine protein concentration and 30 lg of
protein sample was resolved on a 10% SDS–polyacrylamide gel. Fol-
lowing electrophoresis, the protein was transferred to Optitran Sup-
ported Nitrocellulose (Schleicher & Schuell) and blocked using
standard procedures [13]. The membrane was incubated with p21 (187)
sc-817 mouse monoclonal antibody (Santa Cruz Biotechnology) at a
ﬁnal concentration of 200 ng/ml, washed and incubated for a second
time with anti-mouse horseradish peroxidase (Santa Cruz Biotech-
nology) antibody at 100 ng/ml, which was diluted 1:2000. A second
wash was performed prior to blot treatment with Chemiluminescence
Reagents (Perkin–Elmer Life Sciences) and exposure to X-OMAT Blue
XB-1 ﬁlm (Kodak) for detection.
2.6. Transient transfections and CAT assays
Plasmid constructs were isolated and puriﬁed with an EndoFree
Plasmid Maxi Kit (Qiagen). 1.0 lg of WAF1 promoter CAT construct,
2.0 lg of pBlue, 1.0 lg CMV b-Gal, and 85 ll of serum-free DMEM
were mixed together with 10 ll of superfect (Qiagen) and incubated for
20 min at room temperature. The transfection mix was diluted further
with 600 ll DMEM containing 10% FCS and added to directly to
HT29 or HepG2 cells seeded the previous day at 3 106 cells per 35
mm tissue culture plate. Similarly, a transfection mixture containing
1.0 lg of WAF1 promoter CAT construct, 1.0 lg of pBlue, 1.0 lg
CMV b-Gal, and 1.0 lg of CMV c-jun (purchased from ATCC) was
prepared. Transfections were carried out as previously described [15].
The data presented are the result of at least two experiments, each of
which were performed in duplicate.3. Results
Various classes of HDIs have been shown to harbor potent
anti-tumor activities in a range of human tumor cells and
animal models, indicating that these agents may have prom-
ising therapeutic value [3,4]. NaB was one of the ﬁrst HDIs to
be clinically investigated and belongs to the class of short chain
fatty acids. This agent is a non-competitive HDI that exists at
physiologically relevant concentrations within the colon as a
byproduct of anaerobic bacterial fermentation of dietary ﬁber
[5,16]. TSA is a much more potent HDI and belongs to the
group of hydroxamic acids [17]. Although, structurally dis-
similar, both NaB and TSA are capable of promoting cell cyclearrest, diﬀerentiation, and/or apoptosis in tumor cells, where
induction of p21WAF1 by HDIs appears to be important for
suppression of cellular proliferation [7]. To investigate whether
HDIs had anti-proliferative eﬀects in the HepG2 cells, these
hepatocellular carcinoma cells were cultured alone or with
diﬀerent concentrations of NaB or TSA for 24, 48, 72, and
96 h. Growth curve analyses indicated that NaB decreased cell
growth in a dose dependent manner. A dose of 1.0 mM NaB
was capable of inhibiting cellular proliferation and 2.0 mM
NaB was optimal for preventing growth of HepG2 cells (Fig.
1A). TSA, on the other hand, inhibited cell growth at signiﬁ-
cantly lower concentrations, where 1.0 lM TSA was suﬃcient
for the complete absence of HepG2 cellular proliferation (Fig.
1B). Trypan blue staining conﬁrmed the viability of HepG2
cells following 96 h of HDI treatment at the optimal doses.
Given that HDIs appear to be eﬀective anti-proliferative
agents in HepG2 cells, we investigated whether p21WAF1
expression was upregulated by HDIs independent of de novo
protein synthesis, similar to a number of previously docu-
mented examples [8,13]. Time course studies performed in
the presence of NaB (5 mM) indicated a dramatic increase
in the p21WAF1 levels in a time dependent manner, as we
have previously observed (Fig. 2A, top left panel and B)
[13]. Furthermore, TSA (1 lM), was also capable of in-
creasing p21WAF1 protein expression (Fig. 2C). However, we
were surprised to ﬁnd that NaB mediated induction of
p21WAF1 was blocked in the presence of a protein synthesis
inhibitor, Cycloheximide (Fig. 2A, top right panel). North-
ern blots re-probed with c-Src indicated that NaB was ca-
pable of repressing the mRNA expression of this oncogene
independent of new protein synthesis (Fig. 2A, bottom
panels) [13]. Cumulatively, these observations suggest that
p21WAF1 may be an indirect target of HDIs in HepG2 cells.
To our knowledge this is the ﬁrst example where protein neo
synthesis is required for HDI mediated p21WAF1 induction.
Since NaB appears to stimulate p21WAF1 gene expression
dependent on de novo protein synthesis, we next inquired
whether the WAF1 promoter could still be activated by HDIs.
Transient transfection assays were performed in HepG2 cells
with WAF1 CAT promoter constructs in the absence or pres-
ence of HDIs. Several reports have shown that induction of
p21WAF1 byHDIs occurs independently of p53, but requires one
or more Sp1 binding sites located in the proximal promoter [7–
9]. Here we examined two diﬀerent WAF1 CAT promoter
constructs to determine if the WAF1 promoter could be acti-
vated byHDIs inHepG2 cells. These constructs have previously
been shown to be inducible by HDIs in a number of reports [7–
9]. Cells were transiently transfectedwithWAF1CATpromoter
constructs and treatedwith eitherNaBorTSA. Interestingly, we
observed that neither the)210WAF1CAT or)101WAF1CAT
promoter constructs could be activated in HepG2 cells by TSA,
and were only marginally upregulated by NaB (Fig. 3C). A
larger construct, )2300WAF1 CAT, which harbours two p53
response elements was similarly unresponsive to the presences of
HDIs in HepG2 cells (results not shown). In contrast, transient
transfections performed in HT29 cells veriﬁed that the WAF1
promoter constructs were activated as expected. In these cells
the promoter activity of)210WAF1CATwas increased 15- and
30-fold, respectively, by NaB and TSA. Similarly, the
)101WAF1 CAT promoter construct was activated approxi-
mately 6- and 4-fold by NaB and TSA respectively (Fig. 3B).
Since p21WAF1 is constitutively expressed at low levels inHepG2
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Fig. 1. HDIs decrease cellular proliferation in HepG2 cells. Growth
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the average of two independent experiments and includes standard
deviations.
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Fig. 3. The WAF1 promoter is not activated by HDIs in HepG2 cells.
(A) Diagram representing various WAF1 CAT constructs used in this
study showing the positions of critical Sp1 sites. HT29 (B) or HepG2
(C) cells were transiently transfected with WAF1 CAT promoter
constructs; )210WAF1 CAT and )101WAF1 CAT. (B,C) Co-trans-
fections were performed with the WAF1 promoter constructs and
exposed to NaB (5 mM), TSA (1 lM), or left untreated. A second set
of co-transfections were performed with the WAF1 promoter con-
structs and c-jun. The CAT levels were determined relative to the
untreated WAF1 co-transfected HT29 (B) and HepG2 cells (C). Re-
sults represent two independent experiments performed in duplicate.
Fig. 2. HDI upregulation of p21WAF1 gene expression in HepG2 cells
requires protein neo synthesis. (A) Total RNA was extracted from
HepG2 cells following various periods of exposure to NaB (5 mM),
CHX (50 lM), or a combination of the two. RNA was examined by
Northern blot analysis for p21WAF1 and c-Src. (B) Total cellular ex-
tracts were isolated from HepG2 cells following incubation with NaB
(5 mM) or TSA (1 lM) for varying time points and analyzed by
Western blot for p21WAF1 protein expression.
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tually capable of any supplemental transcriptional activation.
Co-transfection experiments were therefore performed with the
WAF1 promoter constructs in the presence of a known p21WAF1
trans-activator, c-jun [18]. Co-transfection data conﬁrmed that
the WAF1 promoter was capable of further activation, being
upregulated by c-jun inHepG2 cells approximately 2.5- and 6.0-fold in )210WAF1 CAT and )101WAF1 CAT activity, re-
spectively (Fig. 3C). Lastly, nuclear run-on assays suggested
that the rate of WAF1 transcription did not increase following
NaB or TSA treatment in HepG2 cells (results not shown).
Therefore, these observations show that the WAF1 promoter is
unresponsive to HDIs, and that post-transcriptional mecha-
nisms must be responsible for the observed induction of
p21WAF1 expression in HepG2 cells.
We next performed a series of mRNA half-life studies in
HepG2 cells. Act. D was added to HepG2 cells to prevent
transcription followed by a 12 h incubation period in the
presence or absence of HDIs. Northern blot analysis was
performed on the mRNA samples and p21WAF1 mRNA levels
were examined (Fig. 4A, top panels). Ribosomal protein PO
(RPPO) was used as a control to normalize the data (Fig. 4A,
bottom panels). The half-life of p21WAF1 mRNA in control
HepG2 cells was calculated to be approximately 85 min.
However, in HepG2 cells treated with NaB or TSA the
p21WAF1 mRNA half-life increased approximately 3.1-fold
(270 min) and 5.4-fold (460 min), respectively (Fig. 4B). Taken
together, our data show that the HDIs, NaB and TSA upre-
gulate p21WAF1 mRNA and protein levels by post-transcrip-
tional mechanisms in HepG2 cells. These results represent the
ﬁrst reported example of HDI mediated mRNA stabilization.
Fig. 4. HDIs increase the stability of p21WAF1 mRNA in HepG2 cells.
(A) Total RNA was isolated from HepG2 cells treated with Act. D in
the presence or absence of NaB (5 mM) or TSA (1 lM) and examined
by Northern blot analysis for p21WAF1 and RPPO. (B) The p21WAF1
mRNA signal was determined by a Molecular Imager and normalized
to the RPPO mRNA signal. Data were plotted on a semi-logarithmic
scale and represent means the standard errors of the means of two
independent experiments.
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HDIs represent a diverse array of structurally distinct com-
pounds that are being extensively studied for their chemopre-
ventative and therapeutic activities in a number of neoplasias.
While HDIs are known to cause cell cycle arrest, diﬀerentiation
and/or apoptosis the mechanisms associated with these anti-
tumor activities have yet to be uncovered. Characteristically,
HDIs have been documented to be transcriptional activators,
althoughmore recent accounts have indicated that HDIs do not
solely alter chromatin dynamics to stimulate gene transcription
but rather appear tobe capable ofmuchmorediverse events. For
instance, HDIs have been implicated in the acetylation of nu-
merous non-histone proteins including the transcription factors,
p53 and E2F1 [6]. Furthermore, the mechanisms responsible for
HDI mediated repression of gene expression have yet to be
elucidated [12,13]. Here we have demonstrated for the ﬁrst time
that HDIs are also capable of regulating gene expression levels
by post-transcriptional mechanisms. In this study, we deter-
mined that treatment of HepG2 cells with HDIs resulted in an
impressive induction of p21WAF1 mRNA and protein. However,
this induction was not the result of transcriptional activation
and required protein neo-synthesis, in contrast to numerous
reports in other cell lines. These results were conﬁrmed in
transfection studies with various WAF1 promoter constructs,
including the full-length, )2300 WAF1 CAT, construct. Al-
though we noted a very minor NaBmediated increase inWAF1
promoter activity this was not seen with the more speciﬁc HDI,
TSA. However, both NaB and TSA dramatically enhanced
p21WAF1 mRNA stability and produced an approximately 3.1-
and 5.4-fold increase, respectively, in HepG2 cells, indicating
that post-transcriptional events play a dominant role in HDImediated upregulation of p21WAF1 in HepG2 cells. Stabilization
of p21WAF1 mRNA has been noted before. For example, Elav-
like proteins binding to AU-rich region of the 30 non-coding
region have been implicated in UVC mediated stability of
p21WAF1 mRNA [19]. However, we have determined that the
AU-rich region of the p21WAF1 mRNA does not display in-
creased binding following HDI treatment (results not shown).
Therefore, it is unlikely that Elav-like proteins are responsible
for HDI mediated upregulation of the p21WAF1 mRNA in
HepG2 cells. Clearly further work will be required to determine
the mechanism of HDI mediated mRNA stabilization.
Taken together these observations suggest that HDIs have
the potential to inﬂuence p21WAF1 gene expression levels in-
dependent of chromatin remodeling and transcriptional acti-
vation, at least in some cell lines. Furthermore, HDI mediated
changes in the mRNA stability may be more universal, and
function in collaboration with histone acetylation to inﬂuence
changes in gene expression. Although the work described here
relates to a single cell line future work regarding such HDI
mediated changes in gene expression must take these obser-
vations into account.
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